Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1119 in Stable Coronary Artery Disease
NCT07884136Phase 2Not yet recruiting
- Sponsor
- Ribocure Pharmaceuticals AB
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 2
01
Overview
A Phase 2 trial of RBD1119 in coronary artery disease (CAD), sponsored by Ribocure Pharmaceuticals AB. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
RBD1119
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07884136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884136.